← FDA DRUG APPROVALS

FDA NDA · NDA022388

ACUVUE THERAVISION WITH KETOTIFEN

Sponsor: JOHNSON JOHNSON VISN

APPLICATION
NDA022388
TYPE
NDA
ORIGINAL APPROVAL
2022-02-25
LATEST ACTION
2022-02-25
ROUTE
OPHTHALMIC
DOSAGE FORM
DRUG-ELUTING CONTACT LENS
MARKETING STATUS
Discontinued

Products

ACUVUE THERAVISION WITH KETOTIFEN · ReferenceDiscontinued
KETOTIFEN FUMARATE EQ 19MCG BASE · DRUG-ELUTING CONTACT LENS · OPHTHALMIC

Approval history

2022-02-25Type 3 - New Dosage Form and Type 4 - New Combination · Original · standard — Label ↗AP
2022-02-25Type 3 - New Dosage Form · Supplement 1 · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →